Clinical Trial

Atrioventricular Block and Cluster Headache (SEVA)

Study acronym: SEVA
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-05-22; most recent amendment 2025-11-25.
Status change: Recruiting → Active, Not Recruiting 2025-11-25
Status change: Not Yet Recruiting → Recruiting 2023-01-23
Trial Details
NCT Number NCT04406259
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Cluster Headache
Enrollment 60 participants
Start Date 2020-11-02
Primary Completion 2025-09-05 (estimated)
Study Completion 2027-09-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-02